Sex steroids and breast density predict breast cancer risk

Article

Both circulating sex steroid levels and mammographic density are strong and independent predictors of breast Ca risk in postmenopausal women. . .

Both circulating sex steroid levels and mammographic density are strong and independent predictors of breast cancer risk in postmenopausal women, according to the results of a nested case-control study.

Using a cohort of 253 women with breast cancer and 520 controls within the Nurses' Health Study, researchers found that women in the highest quartile for mammographic density had almost four times the risk for breast cancer as women in the lowest quartile (RR 3.8; 95% CI, 2.2–6.6; Ptrend<0.001). Adjusting the analysis for circulating estradiol or circulating testosterone made little change (RR 3.9; 95% CI, 2.2–6.0; Ptrend<0.001; and RR 4.1; 95% CI, 2.3–7.2, Ptrend<0.001, respectively). Women with high levels of circulating estradiol or circulating testosterone had about twice as high a risk for developing breast cancer as women with low levels, before and after adjustment for mammographic density (RR 2.4; 95% CI, 1.4–4.0; and RR 2.0; 95% CI, 1.2–3.1, respectively). Women who had both high levels of plasma testosterone and very dense breasts were at six times the risk for breast cancer as women in the lowest tertiles for both (RR 6.0; 95% CI, 2.6–14.0). Figures were similar for women with both high circulating estradiol and mammographic density (RR 4.1; 95% CI, 1.7–9.8).

Tamimi RM, Byrne C, Colditz GA, et al. Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 2007;99:1178-1187.

Recent Videos
Expert discussions from the 2025 ACOG meeting | Image Credit: © stevengaertner - © stevengaertner - stock.adobe.com.
Trina Mansour, MD
Negative pressure wound therapy reduces c-section infections and costs | Image Credit: doctors.valleyhealth.com.
Amy Valent DO, MCR, highlights new tech for prenatal diabetes management | Image Credit: linkedin.com.
Lisa Bayer, MD, MPH
Megan Wasson, DO, FACOG
Megan Cohen, MD, MPH, outlines 2024 CDC contraception guidelines | Image Credit: linkedin.com.
Wasson and Colak
Johanna Finkle, MD, weight loss specialist, OB/GYN, The University of Kansas Health System.
Navigating hormone therapy in high-risk menopause cases | Image Credit: © dhaj7-cepo.com.
© 2025 MJH Life Sciences

All rights reserved.